The head of German pharmaceutical company BioNTech said Monday that there is no need to waive patents on coronavirus vaccines because manufacturers will be able to produce enough shots to supply the world over the coming year.
Ugur Sahin, the chief executive of BioNTech, rejected the US-backed proposal to temporarily lift some intellectual property rights for vaccines.
In a call with investors announcing the company's first-quarter net profit of USD 1.37 billion, Sahin said BioNTech and its US partner Pfizer had already delivered vaccines to more than 90 countries and more than doubled its forecast production capacity for the year.